United Therapeutics Corporation $UTHR Shares Acquired by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd increased its position in United Therapeutics Corporation (NASDAQ:UTHR) by 316.7% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,315 shares of the biotechnology company’s stock after acquiring an additional 13,160 shares during the period. Y Intercept Hong Kong Ltd’s holdings in United Therapeutics were worth $4,975,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. CWM LLC grew its holdings in shares of United Therapeutics by 204.3% in the 2nd quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock worth $1,492,000 after acquiring an additional 3,487 shares during the period. XTX Topco Ltd purchased a new stake in United Therapeutics in the 1st quarter valued at approximately $313,000. Allianz Asset Management GmbH lifted its stake in United Therapeutics by 96.9% in the 1st quarter. Allianz Asset Management GmbH now owns 67,576 shares of the biotechnology company’s stock valued at $20,832,000 after buying an additional 33,254 shares in the last quarter. LPL Financial LLC lifted its stake in United Therapeutics by 77.3% in the 1st quarter. LPL Financial LLC now owns 25,246 shares of the biotechnology company’s stock valued at $7,783,000 after buying an additional 11,007 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in United Therapeutics by 11.4% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,678 shares of the biotechnology company’s stock valued at $1,129,000 after buying an additional 376 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of recent research reports. UBS Group upped their target price on United Therapeutics from $560.00 to $580.00 and gave the company a “buy” rating in a research note on Monday, September 29th. JPMorgan Chase & Co. reduced their target price on United Therapeutics from $350.00 to $330.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 8th. Wells Fargo & Company initiated coverage on United Therapeutics in a research note on Monday, October 20th. They issued an “underweight” rating and a $414.00 target price on the stock. Bank of America raised their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 2nd. Finally, Cantor Fitzgerald raised their target price on shares of United Therapeutics from $405.00 to $525.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 10th. Nine analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $461.62.

Insider Buying and Selling at United Therapeutics

In related news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $308.75, for a total value of $3,396,250.00. Following the transaction, the executive vice president directly owned 36,781 shares of the company’s stock, valued at approximately $11,356,133.75. This trade represents a 23.02% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The SEC filing for this sale provides additional information. Insiders sold a total of 349,435 shares of company stock worth $144,451,272 over the last ninety days. Corporate insiders own 10.30% of the company’s stock.

United Therapeutics Stock Down 1.4%

Shares of United Therapeutics stock opened at $415.34 on Wednesday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $459.48. The firm has a market cap of $18.74 billion, a PE ratio of 16.21, a P/E/G ratio of 4.59 and a beta of 0.66. The business’s fifty day moving average is $401.57 and its two-hundred day moving average is $334.83.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The business had revenue of $798.60 million for the quarter, compared to analysts’ expectations of $802.13 million. During the same period in the prior year, the company earned $5.85 EPS. The company’s revenue for the quarter was up 11.7% compared to the same quarter last year. Equities research analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.